Compare GENB & PSEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GENB | PSEC |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.3B |
| IPO Year | N/A | N/A |
| Metric | GENB | PSEC |
|---|---|---|
| Price | $12.25 | $2.53 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 709.7K | ★ 3.6M |
| Earning Date | 05-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 21.60% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.00 | $2.45 |
| 52 Week High | $13.95 | $4.28 |
| Indicator | GENB | PSEC |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 37.50 |
| Support Level | $11.26 | N/A |
| Resistance Level | $13.70 | $2.82 |
| Average True Range (ATR) | 0.96 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 39.81 | 20.29 |
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.